Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Orchard Therapeutics closes $110mm Series B

Executive Summary

Orchard Therapeutics (gene therapies for rare diseases) raised $110mm (£85mm) through an oversubscribed Series B financing co-led by Baillie Gifford and ORI Capital (adds a board member), which were joined by first-time backers Temasek, Cowen Healthcare Investments, Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, and 4BIO Capital and returning shareholders F-Prime Capital and UCL Technology Fund. The company will use the proceeds for pipeline development including lead program OTL101, which is in Phase III for adenosine deaminase severe combined immunodeficiency. The candidate already has breakthrough therapy designation from the FDA. Orchard has earlier-stage compounds for X-linked chronic granulomatous disease and Sanfilippo syndromes Type A and B. Additional Series B funds will help expand its manufacturing infrastructure and for business development activities.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies